In the last trading session, 2,398,609 Regulus Therapeutics Inc. (NASDAQ:RGLS) shares changed hands as the company’s beta touched 2.28. With the company’s per share price at $0.88 changed hands at -$0.01 or -0.01% during last session, the market valuation stood at $65.84 Million. RGLS’s last price was a discount, traded about -163.64% off its 52-week high of $2.32. The share price had its 52-week low at $0.42, which suggests the last value was 52.27% up since then. When we look at Regulus Therapeutics Inc.’s average trading volume, we note the 10-day average is 4.88 Million shares, with the 3-month average coming to 2.81 Million.
Analysts gave the Regulus Therapeutics Inc. (RGLS) stock a consensus recommendation rating of Overweight, calculated at a mean rating of 2.7. If we narrow down to specifics, the data shows that none out of 3 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, 2 recommended RGLS as a Hold, 1 felt it is a Buy and none rated the stock as Underweight. Regulus Therapeutics Inc.’s EPS for the current quarter is expected to be -$0.08.
Regulus Therapeutics Inc. (NASDAQ:RGLS) trade information
Although RGLS has turned red as seen at the end of in last trading. With action -1.27%, the performance over the past five days has been red. The jump to weekly highs of $1.05 on Monday, Jun 14 added 16.3% to the stock’s daily price. The company’s shares are showing year-to-date downside of -0.35%, with the 5-day performance at -0.16% in the red. However, in the 30-day time frame, Regulus Therapeutics Inc. (NASDAQ:RGLS) is -0.16% down. Looking at the short shares, we see there were 5.91 Million shares sold at short interest cover period of 2.1 days.
The consensus price target for the stock as assigned by Wall Street analysts is $1.17, meaning bulls need an upside of 32.95% from its current market value. According to analyst projections, RGLS’s forecast low is $0.5 with $2 as the target high. To hit the forecast high, the stock’s price needs a +127.27% upsurge from its current level, while the stock would need to tank -43.18% for it to hit the projected low.
Regulus Therapeutics Inc. (RGLS) estimates and forecasts
Data shows that the Regulus Therapeutics Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value dive -19.38% over the past 6 months, a 26.67% in annual growth rate that is considerably higher than the industry average of 16.4%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for Regulus Therapeutics Inc. will rise +65.2%, while the growth in revenue is estimated to hit -100% for the next quarter. Year-over-year growth is forecast to reach -99.8% down from the last financial year.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 49%. The 2021 estimates are for Regulus Therapeutics Inc. earnings to increase by 58.2%, but the outlook for the next 5-year period is at 39.6% per year.
Regulus Therapeutics Inc. (NASDAQ:RGLS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.95% of Regulus Therapeutics Inc. shares while 49.7% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 52.29%. There are 49 institutions holding the Regulus Therapeutics Inc. stock share, with NEA Management Company, LLC the top institutional holder. As of Mar 30, 2021, the company held 8.62% of the shares, roughly 6.45 Million RGLS shares worth $10.06 Million.
Vanguard Group, Inc. (The) holds the second largest percentage of outstanding shares, with 4.3% or 3.22 Million shares worth $5.02 Million as of Mar 30, 2021.
Among Mutual Funds, the top two as of Jan 30, 2021 were USAA Mutual Fund Tr-Science & Technology Fund and Victory Portfolios-Victory RS Science & Technology Fund. With 6270099 shares estimated at $8.72 Million under it, the former controlled 8.38% of total outstanding shares. On the other hand, Victory Portfolios-Victory RS Science & Technology Fund held about 4.13% of the shares, roughly 3.09 Million shares worth around $4.83 Million.